MSK exam 2 C

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/47

encourage image

There's no tags or description

Looks like no tags are added yet.

48 Terms

1
New cards

constipation is from

activated mu receptors in the gut, which decrease acetylcholine and peristalsis, and increases muscle tone

2
New cards

constipation is worsened by

ondansetron, amitriptyline, scopolamine

3
New cards

constipation treatment goal

level 4 stool with prophylaxis

4
New cards

bulk forming laxatives

psyllium, methylcellulose

5
New cards

bulk forming laxatives with opioids

will not work; add bulk without helping motility

6
New cards

docusate moa

anionic surfactant mixes water and fat

7
New cards

docusate use

wastes money and doesn’t work

8
New cards

lubiprostone moa

increases Cl and fluid secretion to the GI tract

9
New cards

lubiprostone use

avoid with methadone, which inhibits Cl secretion

10
New cards

osmotic laxatives

PEG/miralax, glycerin

11
New cards

PEG moa

nonabsorbable, acts in colon at 3 days

12
New cards

PEG dose

17 g TID in 8 oz of liquid

13
New cards

glycerin moa

nonabsorbable, acts in rectum at 30 minutes

14
New cards

glycerin suppository

cannot use in neutropenic patients

15
New cards

stimulant laxatives

senna, bisacodyl

16
New cards

senna moa

stimulates intestinal mucosal nerve plexus

17
New cards

senna dose

4 tabs Q12h, works at 8-12 hours

18
New cards

PAMORAs and moa

methylnaltrexone, naloxegel

peripheral mu receptor antagonists (don’t cross BBB)

19
New cards

PAMORAs used when

no bowel obstruction, last line

20
New cards

methylnaltrexone notes

adjust if CrCl < 60, works too fast

21
New cards

naloxegel notes

adjust if CrCl < 60, 3A4 interactions

22
New cards

urinary retention is from

activated mu receptors which reduce bladder contraction

23
New cards

urinary retention is worsened by

active metabolites, epidural administration, cyclobenzaprine, amitriptyline, scopolamine

24
New cards

management of urinary retention

avoid active metabolites, switch to oral, PAMORA

25
New cards

what opioids do not have active metabolites

fentanyl, tapentadol, oxymorphone, methadone

26
New cards

sedation inducing drugs

alprazolam, gabapentin, amitriptyline, scopolamine, alcohol

27
New cards

sedation management

do not drive for 7 days after opioid dose change, or 6 hours after IR dose

28
New cards

sedation treatment

methylphenidate

29
New cards

n/v occurs with

active metabolites after day 5, females, under 50 y/o, constipation

30
New cards

n/v prophylaxis is given if

patient has history; haloperidol or prochlorperazine

31
New cards

n/v treatment

haloperidol or prochlorperazine after 5 days, address constipation

32
New cards

pruritis occurs with

epidural administration, ER, morphine

33
New cards

pruritis moa

central (NT release) and peripheral (mast cell degranulation)

34
New cards

pruritis managment

change route of administration, rotate opioid

35
New cards

pruritis prophylaxis is given if

intrathecal/epidural administration

36
New cards

pruritis treatment

naloxone, naltrexone, nalbuphine, gabapentin, ondansetron

37
New cards

hypotension occurs with

morphine, dehydration, IV push

38
New cards

hypotension management

change administration, fentanyl, fluid bolus

39
New cards

delirium occurs with

active metabolites, elderly, dose increase

40
New cards

delirium treatment

opioid rotation, treat constipation, ketamine

41
New cards

OPIAD occurs with

dose > 100, chronic therapy, intrathecal administration, ER, fentanyl, oxycodone, methadone

42
New cards

OPIAD treatment

reduce dose, check labs, buprenorphine

43
New cards

slow tapering

decrease TDD by less than 10% per month

44
New cards

fast tapering

decrease TDD by 10% per week, and at 30% OG dose do 10% of remaining dose per week

45
New cards

immunosuppression occurs with

ER/LA, high dose, codeine, morphine, methadone, fentanyl

46
New cards

immunosuppression management

reduce dose, treat infection, buprenorphine

47
New cards

hyperalgesia moa

glial cell activation (sub P and glutamate release), NMDA activation (central sensitization), and 3-glucuronides

48
New cards

hyperalgesia treatment

reduce/taper opioid, avoid H3G+M3G, give NMDA antagonist